ビオフェルミン製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証1部 | 医薬品 | 4517/E00960 | BIOFERMIN PHARMACEUTICAL CO.,LTD. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2019/11/22 | 日証協 | 29,778株 | -1% | 7,500株 | +150% | 22,269株 | -11.87% | 1,500株 | +63.04% |
2019/11/15 | 日証協 | 30,078株 | -3.53% | 3,000株 | +36.36% | 25,269株 | -6.92% | 920株 | -45.95% |
2019/11/08 | 日証協 | 31,178株 | -5% | 2,200株 | -73.55% | 27,147株 | -8.25% | 1,702株 | -43.68% |
2019/11/01 | 日証協 | 32,819株 | +8.03% | 8,319株 | -39.28% | 29,588株 | -0.32% | 3,022株 | +235.78% |
2019/10/25 | 日証協 | 30,380株 | +47.62% | 13,700株 | +7511.11% | 29,683株 | -11.35% | 900株 | -44.44% |
2019/10/18 | 日証協 | 20,580株 | +17.6% | 180株 | -98.16% | 33,483株 | -36.56% | 1,620株 | -69.45% |
2019/10/11 | 日証協 | 17,500株 | -37.5% | 9,800株 | -35.17% | 52,783株 | -1.86% | 5,302株 | -24.78% |
2019/10/04 | 日証協 | 28,001株 | +50.54% | 15,116株 | +214.92% | 53,782株 | -7.21% | 7,049株 | -34.77% |
2019/09/27 | 日証協 | 18,600株 | +0.54% | 4,800株 | +6.67% | 57,964株 | +6.98% | 10,806株 | +68.84% |
2019/09/20 | 日証協 | 18,500株 | -39.74% | 4,500株 | +24.45% | 54,181株 | -32.6% | 6,400株 | -71.61% |
2019/09/13 | 日証協 | 30,700株 | +4.14% | 3,616株 | +206.44% | 80,382株 | +22.09% | 22,543株 | +1749.3% |
2019/09/06 | 日証協 | 29,480株 | -5.75% | 1,180株 | -60.4% | 65,839株 | -7.06% | 1,219株 | -67.13% |
2019/08/30 | 日証協 | 31,280株 | -2.83% | 2,980株 | +496% | 70,840株 | -10.03% | 3,709株 | -54.21% |
2019/08/23 | 日証協 | 32,190株 | -9.04% | 500株 | -78.17% | 78,740株 | +3.96% | 8,100株 | +84.13% |
2019/08/16 | 日証協 | 35,390株 | -4.58% | 2,290株 | -55.1% | 75,740株 | -4.05% | 4,399株 | -33.37% |
2019/08/09 | 日証協 | 37,090株 | +1.64% | 5,100株 | -26.19% | 78,940株 | +3.68% | 6,602株 | +50.01% |
2019/08/02 | 日証協 | 36,490株 | +24.58% | 6,910株 | -34.81% | 76,138株 | +1.74% | 4,401株 | -10.18% |
2019/07/26 | 日証協 | 29,290株 | +34.42% | 10,600株 | +457.89% | 74,837株 | -4.22% | 4,900株 | +133.33% |
2019/07/19 | 日証協 | 21,790株 | +3.32% | 1,900株 | -13.24% | 78,137株 | -3.14% | 2,100株 | -3.14% |
※株式分割は考慮していませんのでご注意ください。